Impact on Therapy
Measuring NCEP ATP III emerging risk factors and secondary targets of therapy is also key to determining the appropriate mix of therapies from among the growing list of available treatment options. Various statins have differing effects on LDL, LDL size, Lp(a), HDL2, and VLDL2. Other agents, such as gemfibrozil, fenofibrate, niacin, and omega-3 fatty acids also have varying effects on LDL size, Lp(a), and HDL2. As a result, VAP Technology is vital for directing appropriate cholesterol-lowering therapy in at-risk patients.